Chronic obstructive pulmonary disease (COPD) involves irreversible loss of lung parenchyma (emphysema) and small-airway inflammation, progressively restricting airflow and oxygen exchange.
Chronic obstructive pulmonary disease (COPD) involves irreversible loss of lung parenchyma (emphysema) and small-airway inflammation, progressively restricting airflow and oxygen exchange. Conventional therapy (bronchodilators, corticosteroids) suppresses inflammation but does not repair alveolar damage. Stem cell strategies target structural restoration: placental mesenchymal stem cells (MSCs) secrete hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) that stimulate alveolar regeneration and angiogenesis, partially reconstituting gas-exchange surface. Exosomes from MSCs reduce alveolar inflammation and oxidative stress. The therapeutic hypothesis challenges the dogma of irreversibility; evidence suggests modest alveolar regeneration is possible, particularly in early-to-moderate disease. Thirty-four registered trials investigate COPD cell therapy; ten actively recruit, indicating expanding clinical interest.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €16,560–€23,000 (cellmedicine.com) |
| 研究的主要细胞类型 | MSCs from Amniotic Membrane, Exosomes |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 34 · 10 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published trials of intravenous placental MSC infusion in moderate-to-severe COPD report improvements in forced expiratory volume (FEV1) of 5–15% over 6–12 months in 40–55% of participants, with associated dyspnoea reduction (Modified Medical Research Council dyspnoea scale) in 50–65%. A phase II trial (68 patients, GOLD grade II–III) demonstrated sustained FEV1 improvement and quality-of-life gains at 12 months in treated versus sham-injected controls. CT imaging in responders shows subtle increases in low-attenuation area density, interpreted as reduced emphysema progression. Exosome inhalation is emerging with small proofs-of-concept showing reduced sputum inflammatory biomarkers and improved cough. Improvement is typically modest (≤15% FEV1 gain); dramatic FEV1 recovery is not observed.
Depending on assessment, a COPD & Lung Disease protocol may draw on:
COPD cell therapy costs €5,000–7,500 per protocol in specialised respiratory centres. Intravenous MSC infusion (€5,500–6,500) is standard. Inhaled exosome therapy (€4,500–5,500) is emerging and may be more cost-effective. Multiple infusions (2–4 over 6 months) increase total cost to €10,000–25,000. Concomitant conventional COPD management (medications, pulmonary rehabilitation) is mandatory and separately funded. Insurance coverage is rare; a few European countries (Spain, Portugal) selectively reimburse for severe COPD (GOLD grade III–IV) with significant disability and failed optimised conventional therapy.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the COPD & Lung Disease cost-by-country breakdown, or compare the best countries for COPD & Lung Disease →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits COPD & Lung Disease.
完整慢性阻塞性肺病和肺部疾病常见问题 → · 慢性阻塞性肺病和肺部疾病成本分解 →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估